Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

This study is testing a drug called CTO1681 to see if it can prevent or reduce cytokine release syndrome (CRS) — a dangerous inflammatory reaction — in people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who are receiving CAR T-cell therapy (a form of immunotherapy). **You may be eligible if...** - You are 18 or older with relapsed or refractory DLBCL - You are scheduled to receive a specific commercial CAR T-cell therapy (axicabtagene ciloleucel or lisocabtagene maraleucel) - You have adequate heart, kidney, and liver function - You are able to take oral medications **You may NOT be eligible if...** - You have had a recent heart attack or stroke (within 6 months) - You have significant heart rhythm problems or require blood thinners at a therapeutic dose - You have uncontrolled blood pressure below 100 mmHg - You have an autoimmune disease that required immune-suppressing treatment in the past 2 years - You have significant electrolyte imbalances (such as low potassium or sodium) Talk to your doctor to see if this trial is right for you.